Alnylam Pharmaceuticals, Inc. (ALNY) Financials

Key financial figures for Alnylam Pharmaceuticals, Inc. (Q2 2026).

Revenue

$1.3B

Net Income

$164M

EPS

$1.23

Total Assets

$5.6B

Operating Cash Flow

$75M

Full income statement, balance sheet, and cash flow for Alnylam Pharmaceuticals, Inc. on SentiSense.